Drug Profile


Alternative Names: CV 205 502; Norprolac; Prolactin; SDZ 205 502

Latest Information Update: 07 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Aminoquinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Female infertility; Hyperprolactinaemia; Prolactinoma

Most Recent Events

  • 07 Oct 2009 Launched for Hyperprolactinaemia in European Union (PO)
  • 07 Oct 2009 Launched for Hyperprolactinaemia in Hong Kong (PO)
  • 07 Oct 2009 Launched for Hyperprolactinaemia in Mexico (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top